Kris Vaddi, PhD

Kris Vaddi, PhD

Kris Vaddi, Ph.D. is a drug discovery scientist and the founder of cancer focused startup companies Orsenix and Prelude Therapeutics, and a not-for-profit venture Sidus Healthcare. Prior to his new ventures, Kris had a 14-year career at Incyte starting as a founding...
Peggy Scherle, PhD

Peggy Scherle, PhD

Dr. Scherle is Chief Scientific Officer at Prelude. Prior to joining Prelude, Dr. Scherle was Group Vice President, Discovery Biology and Preclinical Pharmacology at Incyte Corporation and oversaw the target validation and drug discovery efforts for both the small and...
Aimee Crombie, PhD

Aimee Crombie, PhD

Aimee Crombie, Ph.D. is Vice President of R&D Operations at Prelude Therapeutics. Prior to joining Prelude, she was Vice President of Research at Trevena, Inc. where she oversaw drug discovery activities supporting target and hit identification, chemical lead...

Kelvin M. Neu

Kelvin M. Neu, M.D. was appointed a member of the Company’s Board in July 2016. Kelvin is a Managing Director of Baker Brothers Investments. The firm manages long-term investment funds focused on publicly traded life sciences companies, for major university endowments...
David Bonita

David Bonita

Dr. David Bonita, M.D., has served as a member of our board of directors since July 2016. Since June 2013, Dr. Bonita has held the position of Private Equity Partner at OrbiMed Advisors LLC, an affiliate of one of our principal shareholders. From June 2004 to June...